Compare Mongodb Inc (MDB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Novo Nordisk A/S — how do they compare? Mongodb Inc trades at $441.06 (market cap $35.32B), while Novo Nordisk A/S trades at $45.96 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.9× Mongodb Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | NVO | |
|---|---|---|
Market Cap | $35.32B | $207.85B |
Sector | Technology | Health |
52-Week High | $440.25 | $63.98 |
52-Week Low | $204.37 | $35.29 |
Enterprise Value | $32.93B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $416.67, up 4.48% in the last session, with a bullish technical setup per moving averages and ADX. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and strong analyst sentiment, with 82% buy ratings, support optimism. The stock is near its pivot point of $412, with resistance at $428.
Outlook: MDB's growth trajectory and AI-driven demand present upside, but profitability concerns and high valuation multiples (P/S 13.73) pose risks. Investors should weigh revenue momentum against persistent losses and competitive pressures in the database software market.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
